Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-01-03
2006-01-03
Balasubramanian, Venkataraman (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S255060, C544S405000, C544S336000
Reexamination Certificate
active
06982267
ABSTRACT:
The present invention relates to compounds represented by the structural Formula I:or a pharmaceutically acceptable salt thereof, which are useful for the treatment of metabolic and eating disorders such as obesity and hyperphagia, and for the treatment of diabetes and associated disorders.
REFERENCES:
patent: 4405644 (1983-09-01), Kabbe
patent: 4623662 (1986-11-01), De Vries
patent: 1 249 233 (2002-10-01), None
patent: WO 96/16542 (1996-06-01), None
patent: WO 99/09024 (1999-02-01), None
patent: WO 00/27845 (2000-05-01), None
patent: WO 01/14376 (2001-03-01), None
patent: WO 01/37826 (2001-05-01), None
Betancur et al., TIPS vol. 18, 372-386, 1997.
Wieland et al., Expert Opin. Investig. Drugs 9(6): 1327-1346,2000.
West, Anthony R. Solid state chemistry and its application, pp. 358, 365, 1988.
Stanley, et al. “Neuropeptide Y injected in the paraventricular hypothalamus: A powerful stimulant of feeding behavior”Proc. Natl. Acad. Sci.82:3940-3943(1985).
Billington, et al. “Effects of intracerebroventricular injection of neuropeptide Y on energy metabolism”Am. J. Physiol.260:R321-R327 (1991).
Wahlestedt, et al. “Neuropeptide Y-related peptides and their receptors—are the receptors potential therapeutic drug targets?”Ann. Rev. Pharmacol. Toxicol.32:309-352 (1993).
Gerald, et al. “A receptor subtype involved in neuropeptide-Y-induced food intake”Nature382:168-171 (1996).
Gehlert, D., “Minireview—Multiple Receptors for the Pancreatic Polypeptide (PP-Fold) Family: Physiological Implications”Proc. Soc. Exp. Biol. Med.218:7-22(1998).
Michel, et al., “XVI. International Union of Pharmacology Recommendations for the Nomenclature of Neuropeptide Y, Peptide YY, and Pancreatic Polypeptide Receptors”Pharmacol. Rev.50(1):143-150(1998).
Hwa, et al. “Activation of the NPY Y5 receptor regulates both feeding and energy expenditure”American J. Physiological277(46):R1428-R1434(1999).
Dong Youhao
McCombie Stuart W.
Stamford Andrew
Wu Yusheng
Balasubramanian Venkataraman
Lee William Y.
Schering Corporation
LandOfFree
Heteroaryl urea neuropeptide Y Y5 receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Heteroaryl urea neuropeptide Y Y5 receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heteroaryl urea neuropeptide Y Y5 receptor antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3585110